These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8170992)

  • 1. In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity.
    Barbas CF; Hu D; Dunlop N; Sawyer L; Cababa D; Hendry RM; Nara PL; Burton DR
    Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3809-13. PubMed ID: 8170992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range.
    Yang WP; Green K; Pinz-Sweeney S; Briones AT; Burton DR; Barbas CF
    J Mol Biol; 1995 Dec; 254(3):392-403. PubMed ID: 7490758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity.
    Thompson J; Pope T; Tung JS; Chan C; Hollis G; Mark G; Johnson KS
    J Mol Biol; 1996 Feb; 256(1):77-88. PubMed ID: 8609615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.
    Zhang MY; Shu Y; Rudolph D; Prabakaran P; Labrijn AF; Zwick MB; Lal RB; Dimitrov DS
    J Mol Biol; 2004 Jan; 335(1):209-19. PubMed ID: 14659751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M; Phogat SK; Shu Y; Labrijn AF; Xiao X; Binley JM; Zhang MY; Sidorov IA; Broder CC; Robinson J; Parren PW; Burton DR; Dimitrov DS
    Proc Natl Acad Sci U S A; 2002 May; 99(10):6913-8. PubMed ID: 11997472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in affinity and HIV-1 neutralization by somatic mutation in the heavy chain first complementarity-determining region of antibodies triggered by HIV-1 infection.
    Torán JL; Sánchez-Pulido L; Kremer L; del Real G; Valencia A; Martínez-A C
    Eur J Immunol; 2001 Jan; 31(1):128-37. PubMed ID: 11169446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
    Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
    J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Envelope cross-reactivity between human immunodeficiency virus types 1 and 2 detected by different serological methods: correlation between cross-neutralization and reactivity against the main neutralizing site.
    Böttiger B; Karlsson A; Andreasson PA; Nauclér A; Costa CM; Norrby E; Biberfeld G
    J Virol; 1990 Jul; 64(7):3492-9. PubMed ID: 2191152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs.
    Prabakaran P; Gan J; Wu YQ; Zhang MY; Dimitrov DS; Ji X
    J Mol Biol; 2006 Mar; 357(1):82-99. PubMed ID: 16426633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
    Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
    Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades.
    Zhang MY; Shu Y; Sidorov I; Dimitrov DS
    Antiviral Res; 2004 Mar; 61(3):161-4. PubMed ID: 15168796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants.
    Li Y; Svehla K; Mathy NL; Voss G; Mascola JR; Wyatt R
    J Virol; 2006 Feb; 80(3):1414-26. PubMed ID: 16415019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
    Yang X; Lipchina I; Cocklin S; Chaiken I; Sodroski J
    J Virol; 2006 Nov; 80(22):11404-8. PubMed ID: 16956933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
    Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
    Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.